ClinicalTrials.gg
TerminatedNCT03400176Updated May 16, 2025Results posted

VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

A Phase 1 interventional study of VAY736 and ibrutinib in Chronic Lymphocytic Leukemia (CLL), sponsored by Novartis Pharmaceuticals. Terminated at 5 sites in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

Why this study was terminated
Business reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Non-randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Novartis — none open to participants now, 1 under way, none of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · Novartis.

Enrollment
7th of 13
39 · median 39
Started
2018
the only one that year
Phase 1
5 of 13
none open now
Registered
11th of 13
by date

Among the 13 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Novartis, this one is the 7th largest by enrollment, is the only one that started in 2018, is one of 5 in phase 1, and was the 11th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

None of the 13 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Novartis is open now. The open studies under Leukemia, Lymphocytic, Chronic, B-Cell, anywhere →

Who these studies take

Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Novartis as a file.
02

Study summary

Patients enrolled to the study had chronic lymphocytic leukemia (CLL) and received ibrutinib. Patients had either received ibrutinib for one year without having had a complete response or patients developed a resistance mutation to ibrutinib. This study had two parts, a dose escalation part and a dose expansion part.

03

Conditions studied

  • Chronic Lymphocytic Leukemia (CLL)

Keywords

  • Ibrutinib
  • VAY736
  • Chronic lymphocytic leukemia
  • CLL
  • Bruton's Tyrosine Kinase
  • BTK mutation
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of CLL per the WHO classification
  • At least 18 years of age
  • Lack of a complete response after receiving ibrutinib for > 1 year OR presence of known ibrutinib resistance mutation
  • Actively receiving ibrutinib at either 420 mg (patients enrolled to the escalation arm) or at a stable dose for at least 2 months prior to starting study treatment (patients enrolled to the expansion arm)

Exclusion criteria

Exclusion Criteria:

  • Known history of
  • Active or C infection
  • Receipt of attenuated vaccine within 2 weeks prior to starting study treatment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Dose Escalation

    Increasing doses of VAY736 in combination with a fixed dose of ibrutinib.

    Drug: VAY736 · Drug: ibrutinib

  • Experimental
    Dose expansion

    Evaluation of the MTD/RD of the combination of VAY736 and ibrutinib that was identified in dose escalation.

    Drug: VAY736 · Drug: ibrutinib

Interventions

  • DrugVAY736

    Experimental

  • Approved medication

    Also known as: Imbruvica

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-Limiting Toxicities (DLTs) in Cycle 1 (Escalation Only)

    A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value of Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 assessed as unrelated to disease, disease progression, inter-current illness or concomitant medications that occurs within the first 28 days of treatment with the combination of VAY736 and ibrutinib and meets the criteria defined in the study protocol. Other clinically significant toxicities may be considered to be DLTs, even if not CTCAE grade 3 or higher.

    Time frame: 28 days

  2. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Number of participants with AEs (any AE regardless of seriousness) and SAEs, including changes from baseline in vital signs, electrocardiograms and laboratory results qualifying and reported as AEs. AE grades to characterize the severity of the AEs were based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. For CTCAE v4.03, Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = death related to AE. All patients were followed for a 30-day safety follow-up period subsequent to completion of VAY736 therapy. No new AEs or SAEs were collected beyond the 30-day safety follow-up or during the efficacy follow up period.

    Time frame: From first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months

  3. Number of Participants With Dose Reductions and Dose Interruptions of VAY736

    For patients who did not tolerate the protocol-specified dosing schedule of the study drugs, dose adjustments could be permitted in order to allow the patient to continue study treatment.

    Time frame: Up to 7.8 months

  4. Number of Participants With Dose Reductions and Dose Interruptions of Ibrutinib

    For patients who did not tolerate the protocol-specified dosing schedule of the study drugs, dose adjustments could be permitted in order to allow the patient to continue study treatment.

    Time frame: Up to 8.5 months

  5. Dose Intensity of VAY736

    Dose intensity of VAY736 was calculated as: Actual Cumulative dose (mg/kg) / (Duration of exposure in weeks/2)

    Time frame: Up to 7.8 months

  6. Dose Intensity of Ibrutinib

    Dose intensity of ibrutinib was calculated as: Actual Cumulative dose (mg) / (Duration of exposure in days)

    Time frame: Up to 8.5 months

Secondary outcomes

  1. CR or CRi Rate at C9 for Expansion Arm A and Arm B by Investigator Per IWCLL

    Percentage of participants with Complete Response (CR) or Complete Response with Incomplete Marrow Recovery (CRi) by investigator assessment per International Working Group - Chronic Lymphocytic Leukemia (IWCLL) response criteria.

    Time frame: Cycle 9 Day 1 (C9). The duration of each cycle was 28 days.

  2. Posterior Mean of CR or CRi Response Rate at C9 for Expansion Arm A and Arm B (Bayesian Analysis)

    The rate of CR/CRi at C9 was analyzed for each expansion arm using a Bayesian modeling approach. A minimally informative beta distribution was used as prior distribution with parameters a=0.25 and b=1. This assumed, a priori, that the response rate was 20%. Values estimated from the model at Cycle 9 are presented in the table. Posterior geometric mean for CR/CRi rate and 90% credible intervals in each group are presented.

    Time frame: Cycle 9 Day 1 (C9). The duration of each cycle was 28 days.

  3. Posterior Probability That the True CR or CRi Response Rate at C9 for Expansion Arm A and Arm B Falls in Pre-defined Activity Intervals (Bayesian Analysis)

    The rate of CR/CRi at C9 was analyzed for each expansion arm using a Bayesian modeling approach. A minimally informative beta distribution was used as prior distribution with parameters a=0.25 and b=1. This assumed, a priori, that the response rate was 20%. Values estimated from the model at Cycle 9 are presented in the table. The posterior probability that the true CR/CRi rate falls in the activity intervals defined below is presented: * \[0, 20%) - clinically not meaningful * \[20%, 40%) - moderate clinical benefit * \[40%, 100%\] - superior clinical benefit

    Time frame: Cycle 9 Day 1 (C9). The duration of each cycle was 28 days.

  4. Overall Response Rate (ORR) Assessed by Investigator Per IWCLL in the Dose Escalation Part

    Efficacy was based on local investigator assessment per International Working Group - Chronic Lymphocytic Leukemia (IWCLL) response criteria. ORR per IWCLL is defined as the percentage of participants with a best overall response of Complete Response (CR), Complete Response with Incomplete Marrow Recovery (CRi) or Partial Response (PR).

    Time frame: Up to approximately 2.5 years

  5. Overall Response Rate (ORR) Assessed by Investigator Per IWCLL in the Dose Expansion Part

    Efficacy was based on local investigator assessment per International Working Group - Chronic Lymphocytic Leukemia (IWCLL) response criteria. ORR per IWCLL is defined as the percentage of participants with a best overall response of Complete Response (CR), Complete Response with Incomplete Marrow Recovery (CRi) or Partial Response (PR).

    Time frame: Up to approximately 2.7 years

  6. Time to Progression (TTP) in the Dose Escalation Part

    Efficacy was based on local investigator assessment per International Working Group - Chronic Lymphocytic Leukemia (IWCLL) response criteria. TTP is defined as the time from start of treatment to date of event which is defined as the first documented progression or death due to underlying cancer. If a patient had not had an event, TTP was censored at the date of the last adequate disease assessment. TTP was analyzed using Kaplan-Meier estimates.

    Time frame: Up to approximately 2.5 years

  7. Time to Progression (TTP) in the Dose Expansion Part

    Efficacy was based on local investigator assessment per International Working Group - Chronic Lymphocytic Leukemia (IWCLL) response criteria. TTP is defined as the time from start of treatment to date of event which is defined as the first documented progression or death due to underlying cancer. If a patient had not had an event, TTP was censored at the date of the last adequate disease assessment. TTP was analyzed using Kaplan-Meier estimates.

    Time frame: Up to approximately 2.7 years

  8. Percentage of Participants With Clearance of Ibrutinib Resistance Mutation During Treatment (up to C9) for Expansion Arm B

    Clearance was defined as less than 1% mutation bearing alleles (BTKC481 and/or PLCγ2) during treatment. Negative mutation is defined as having clearance of the baseline ibrutinib resistance mutation during treatment (up to Cycle 9 (C9)).

    Time frame: Up to Cycle 9 Day 1. The duration of each cycle was 28 days.

  9. Maximum Observed Serum Concentration (Cmax) of VAY736

    Pharmacokinetic (PK) parameters were calculated based on VAY736 serum concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed concentration following a dose.

    Time frame: Pre-infusion and 2, 6, 24, 72, 168 and 336 hours after end of infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of the infusion was approximately 2 hours. 1 cycle=28 days

  10. Time to Reach Maximum Serum Concentration (Tmax) of VAY736

    PK parameters were calculated based on VAY736 serum concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) concentration following a dose. Actual recorded sampling times were considered for the calculations.

    Time frame: Pre-infusion and 2, 6, 24, 72, 168 and 336 hours after end of infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of the infusion was approximately 2 hours. 1 cycle=28 days

  11. Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of VAY736

    PK parameters were calculated based on VAY7736 serum concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation.

    Time frame: Pre-infusion and 2, 6, 24, 72, 168 and 336 hours after end of infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of the infusion was approximately 2 hours. 1 cycle=28 days

  12. Maximum Observed Plasma Concentration (Cmax) of Ibrutinib

    PK parameters were calculated based on ibrutinib plasma concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed concentration following a dose.

    Time frame: Pre-dose and 0.5, 2, 6 and 24 hours post-dose on Cycle 1 Day 1 and Cycle 1 Day 8. 1 cycle=28 days

  13. Time to Reach Maximum Plasma Concentration (Tmax) of Ibrutinib

    PK parameters were calculated based on ibrutinib plasma concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) concentration following a dose. Actual recorded sampling times were considered for the calculations.

    Time frame: Pre-dose and 0.5, 2, 6 and 24 hours post-dose on Cycle 1 Day 1 and Cycle 1 Day 8. 1 cycle=28 days

  14. Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Ibrutinib

    PK parameters were calculated based on ibrutinib plasma concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation.

    Time frame: Pre-dose and 0.5, 2, 6 and 24 hours post-dose on Cycle 1 Day 1 and Cycle 1 Day 8. 1 cycle=28 days

  15. Number of Participants With Anti-VAY736 Antibodies

    VAY736 immunogenicity was evaluated in serum samples. Anti-drug antibodies (ADA) status was defined as follows: * ADA-negative at baseline: baseline sample where assay is ADA negative * ADA-positive at baseline: baseline sample where assay is ADA positive * ADA-negative post-baseline: ADA-negative sample at baseline and at least 1 post-baseline sample, all of which are ADA-negative samples * Treatment-induced ADA-positive: ADA-negative sample at baseline and at least 1 treatment-induced ADA-positive sample * Treatment-boosted ADA-positive: ADA-positive sample at baseline and at least 1 treatment-boosted ADA-positive sample * ADA-inconclusive post-baseline: patient who does not qualify for any of the above definitions

    Time frame: Baseline (before first dose) and post-baseline (assessed throughout the VAY736 treatment, up to 7.8 months).

07

Results

Posted May 13, 2025

Participant flow

A total of 39 patients were enrolled in the study. Fifteen patients participated in the dose escalation part across four treatment arms: VAY736 0.3 mg/kg Q2W + ibrutinib 420 mg, VAY736 1 mg/kg Q2W + ibrutinib 420 mg, VAY736 3 mg/kg Q2W + ibrutinib 420 mg, and VAY735 9 mg/kg + ibrutinib 420 mg. The remaining 24 subjects were enrolled in the expansion part and were treated with VAY736 3 mg/kg Q2W in combination with ibrutinib 420 mg or 280 mg.

Dose Escalation
Participant flow — Dose Escalation
MilestoneVAY736 0.3mg/kg Q2W + Ibrutinib 420mgVAY736 1mg/kg Q2W + Ibrutinib 420mgVAY736 3mg/kg Q2W + Ibrutinib 280mgVAY736 3mg/kg Q2W + Ibrutinib 420mgVAY736 9mg/kg Q2W + Ibrutinib 420mg
Started43044
Completed32042
Not completed11002
Withdrew: Progressive disease11001
Withdrew: Patient decision00001
Dose Expansion
Participant flow — Dose Expansion
MilestoneVAY736 0.3mg/kg Q2W + Ibrutinib 420mgVAY736 1mg/kg Q2W + Ibrutinib 420mgVAY736 3mg/kg Q2W + Ibrutinib 280mgVAY736 3mg/kg Q2W + Ibrutinib 420mgVAY736 9mg/kg Q2W + Ibrutinib 420mg
Started001230
Group a000190
Group b00140
Completed000190
Not completed00140
Withdrew: Patient decision00010
Withdrew: Adverse event00010
Withdrew: Physician decision00010
Withdrew: Progressive disease00110

Outcome measures

PrimaryNumber of Participants With Dose-Limiting Toxicities (DLTs) in Cycle 1 (Escalation Only)

A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value of Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 assessed as unrelated to disease, disease progression, inter-current illness or concomitant medications that occurs within the first 28 days of treatment with the combination of VAY736 and ibrutinib and meets the criteria defined in the study protocol. Other clinically significant toxicities may be considered to be DLTs, even if not CTCAE grade 3 or higher.

Time frame:
28 days
Reported as:
Count of participants · Participants
Number of Participants With Dose-Limiting Toxicities (DLTs) in Cycle 1 (Escalation Only)
ParticipantsVAY736 0.3mg/kg Q2W + Ibrutinib 420mgVAY736 1mg/kg Q2W + Ibrutinib 420mgVAY736 3mg/kg Q2W + Ibrutinib 420mgVAY736 9mg/kg Q2W + Ibrutinib 420mg
Number of Participants With Dose-Limiting Toxicities (DLTs) in Cycle 1 (Escalation Only)0000
PrimaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Number of participants with AEs (any AE regardless of seriousness) and SAEs, including changes from baseline in vital signs, electrocardiograms and laboratory results qualifying and reported as AEs. AE grades to characterize the severity of the AEs were based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. For CTCAE v4.03, Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = death related to AE. All patients were followed for a 30-day safety follow-up period subsequent to completion of VAY736 therapy. No new AEs or SAEs were collected beyond the 30-day safety follow-up or during the efficacy follow up period.

Time frame:
From first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsVAY736 0.3mg/kg Q2W + Ibrutinib 420mgVAY736 1mg/kg Q2W + Ibrutinib 420mgVAY736 3mg/kg Q2W + Ibrutinib 280mgVAY736 3mg/kg Q2W + Ibrutinib 420mgVAY736 9mg/kg Q2W + Ibrutinib 420mg
AEs431274
Treatment-related AEs221151
AEs with grade >=3121120
Treatment-related AEs with grade >=301170
SAEs01010
Treatment-related SAEs01010
Fatal SAEs00000
PrimaryNumber of Participants With Dose Reductions and Dose Interruptions of VAY736

For patients who did not tolerate the protocol-specified dosing schedule of the study drugs, dose adjustments could be permitted in order to allow the patient to continue study treatment.

Time frame:
Up to 7.8 months
Reported as:
Count of participants · Participants
Number of Participants With Dose Reductions and Dose Interruptions of VAY736
ParticipantsVAY736 0.3mg/kg Q2W + Ibrutinib 420mgVAY736 1mg/kg Q2W + Ibrutinib 420mgVAY736 3mg/kg Q2W + Ibrutinib 280mgVAY736 3mg/kg Q2W + Ibrutinib 420mgVAY736 9mg/kg Q2W + Ibrutinib 420mg
At least one dose reduction or interruption01050
At least one dose reduction00010
At least one dose interruption01050
PrimaryNumber of Participants With Dose Reductions and Dose Interruptions of Ibrutinib

For patients who did not tolerate the protocol-specified dosing schedule of the study drugs, dose adjustments could be permitted in order to allow the patient to continue study treatment.

Time frame:
Up to 8.5 months
Reported as:
Count of participants · Participants
Number of Participants With Dose Reductions and Dose Interruptions of Ibrutinib
ParticipantsVAY736 0.3mg/kg Q2W + Ibrutinib 420mgVAY736 1mg/kg Q2W + Ibrutinib 420mgVAY736 3mg/kg Q2W + Ibrutinib 280mgVAY736 3mg/kg Q2W + Ibrutinib 420mgVAY736 9mg/kg Q2W + Ibrutinib 420mg
At least one dose reduction or interruption010100
At least one dose reduction00000
At least one dose interruption010100
PrimaryDose Intensity of VAY736

Dose intensity of VAY736 was calculated as: Actual Cumulative dose (mg/kg) / (Duration of exposure in weeks/2)

Time frame:
Up to 7.8 months
Reported as:
Median · mg/kg/2 weeks
Dose Intensity of VAY736
mg/kg/2 weeksVAY736 0.3mg/kg Q2W + Ibrutinib 420mgVAY736 1mg/kg Q2W + Ibrutinib 420mgVAY736 3mg/kg Q2W + Ibrutinib 280mgVAY736 3mg/kg Q2W + Ibrutinib 420mgVAY736 9mg/kg Q2W + Ibrutinib 420mg
Dose Intensity of VAY7360.30 (0.3 to 0.3)0.98 (0.9 to 1.0)3.00 (3.0 to 3.0)3.00 (1.4 to 3.0)8.97 (8.9 to 9.0)
PrimaryDose Intensity of Ibrutinib

Dose intensity of ibrutinib was calculated as: Actual Cumulative dose (mg) / (Duration of exposure in days)

Time frame:
Up to 8.5 months
Reported as:
Median · mg/day
Dose Intensity of Ibrutinib
mg/dayVAY736 0.3mg/kg Q2W + Ibrutinib 420mgVAY736 1mg/kg Q2W + Ibrutinib 420mgVAY736 3mg/kg Q2W + Ibrutinib 280mgVAY736 3mg/kg Q2W + Ibrutinib 420mgVAY736 9mg/kg Q2W + Ibrutinib 420mg
Dose Intensity of Ibrutinib420.00 (420.0 to 420.0)420.00 (407.7 to 420.0)280.00 (280.0 to 280.0)420.00 (395.7 to 420.0)420.00 (420.0 to 420.0)
SecondaryCR or CRi Rate at C9 for Expansion Arm A and Arm B by Investigator Per IWCLL

Percentage of participants with Complete Response (CR) or Complete Response with Incomplete Marrow Recovery (CRi) by investigator assessment per International Working Group - Chronic Lymphocytic Leukemia (IWCLL) response criteria.

Time frame:
Cycle 9 Day 1 (C9). The duration of each cycle was 28 days.
Reported as:
Number · percentage of participants
CR or CRi Rate at C9 for Expansion Arm A and Arm B by Investigator Per IWCLL
percentage of participantsVAY736 3mg/kg Q2W Arm A + Ibrutinib 420mgVAY736 3mg/kg Q2W Arm B + Ibrutinib 280mgVAY736 3mg/kg Q2W Arm B + Ibrutinib 420mgAll Patients Expansion
CR or CRi Rate at C9 for Expansion Arm A and Arm B by Investigator Per IWCLL47.4 (27.4 to 68.0)0 (0 to 95.0)0 (0 to 52.7)37.5 (21.2 to 56.3)
SecondaryPosterior Mean of CR or CRi Response Rate at C9 for Expansion Arm A and Arm B (Bayesian Analysis)

The rate of CR/CRi at C9 was analyzed for each expansion arm using a Bayesian modeling approach. A minimally informative beta distribution was used as prior distribution with parameters a=0.25 and b=1. This assumed, a priori, that the response rate was 20%. Values estimated from the model at Cycle 9 are presented in the table. Posterior geometric mean for CR/CRi rate and 90% credible intervals in each group are presented.

Time frame:
Cycle 9 Day 1 (C9). The duration of each cycle was 28 days.
Reported as:
Geometric mean · percentage of participants
Posterior Mean of CR or CRi Response Rate at C9 for Expansion Arm A and Arm B (Bayesian Analysis)
percentage of participantsVAY736 3mg/kg Q2W Arm A + Ibrutinib 420mgVAY736 3mg/kg Q2W Arm B + Ibrutinib 280mgVAY736 3mg/kg Q2W Arm B + Ibrutinib 420mgAll Patients Expansion
Posterior Mean of CR or CRi Response Rate at C9 for Expansion Arm A and Arm B (Bayesian Analysis)45.68 (28.1 to 63.7)11.11 (0 to 51.6)4.76 (0 to 23)36.63 (21.8 to 52.7)
SecondaryPosterior Probability That the True CR or CRi Response Rate at C9 for Expansion Arm A and Arm B Falls in Pre-defined Activity Intervals (Bayesian Analysis)

The rate of CR/CRi at C9 was analyzed for each expansion arm using a Bayesian modeling approach. A minimally informative beta distribution was used as prior distribution with parameters a=0.25 and b=1. This assumed, a priori, that the response rate was 20%. Values estimated from the model at Cycle 9 are presented in the table. The posterior probability that the true CR/CRi rate falls in the activity intervals defined below is presented: * \[0, 20%) - clinically not meaningful * \[20%, 40%) - moderate clinical benefit * \[40%, 100%\] - superior clinical benefit

Time frame:
Cycle 9 Day 1 (C9). The duration of each cycle was 28 days.
Reported as:
Number · percentage of participants
Posterior Probability That the True CR or CRi Response Rate at C9 for Expansion Arm A and Arm B Falls in Pre-defined Activity Intervals (Bayesian Analysis)
percentage of participantsVAY736 3mg/kg Q2W Arm A + Ibrutinib 420mgVAY736 3mg/kg Q2W Arm B + Ibrutinib 280mgVAY736 3mg/kg Q2W Arm B + Ibrutinib 420mgAll Patients Expansion
[0, 20%) - clinically not meaningful0.580.293.63
[20%, 40%) - moderate clinical benefit30.411.35.361.8
40%, 100%] - superior clinical benefit69.18.51.135.2
SecondaryOverall Response Rate (ORR) Assessed by Investigator Per IWCLL in the Dose Escalation Part

Efficacy was based on local investigator assessment per International Working Group - Chronic Lymphocytic Leukemia (IWCLL) response criteria. ORR per IWCLL is defined as the percentage of participants with a best overall response of Complete Response (CR), Complete Response with Incomplete Marrow Recovery (CRi) or Partial Response (PR).

Time frame:
Up to approximately 2.5 years
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) Assessed by Investigator Per IWCLL in the Dose Escalation Part
percentage of participantsVAY736 0.3mg/kg Q2W + Ibrutinib 420mgVAY736 1mg/kg Q2W + Ibrutinib 420mgVAY736 3mg/kg Q2W + Ibrutinib 420mgVAY736 9mg/kg Q2W + Ibrutinib 420mgAll Patients Escalation
Overall Response Rate (ORR) Assessed by Investigator Per IWCLL in the Dose Escalation Part50.0 (9.8 to 90.2)0 (0 to 63.2)50.0 (9.8 to 90.2)50.0 (9.8 to 90.2)40.0 (19.1 to 64.0)
SecondaryOverall Response Rate (ORR) Assessed by Investigator Per IWCLL in the Dose Expansion Part

Efficacy was based on local investigator assessment per International Working Group - Chronic Lymphocytic Leukemia (IWCLL) response criteria. ORR per IWCLL is defined as the percentage of participants with a best overall response of Complete Response (CR), Complete Response with Incomplete Marrow Recovery (CRi) or Partial Response (PR).

Time frame:
Up to approximately 2.7 years
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) Assessed by Investigator Per IWCLL in the Dose Expansion Part
percentage of participantsVAY736 3mg/kg Q2W Arm A + Ibrutinib 420mgVAY736 3mg/kg Q2W Arm B + Ibrutinib 280mgVAY736 3mg/kg Q2W Arm B + Ibrutinib 420mgAll Patients Expansion
Overall Response Rate (ORR) Assessed by Investigator Per IWCLL in the Dose Expansion Part84.2 (64.1 to 95.6)0 (0 to 95.0)25.0 (1.3 to 75.1)70.8 (52.1 to 85.4)
SecondaryTime to Progression (TTP) in the Dose Escalation Part

Efficacy was based on local investigator assessment per International Working Group - Chronic Lymphocytic Leukemia (IWCLL) response criteria. TTP is defined as the time from start of treatment to date of event which is defined as the first documented progression or death due to underlying cancer. If a patient had not had an event, TTP was censored at the date of the last adequate disease assessment. TTP was analyzed using Kaplan-Meier estimates.

Time frame:
Up to approximately 2.5 years
Reported as:
Median · months
Time to Progression (TTP) in the Dose Escalation Part
monthsVAY736 0.3mg/kg Q2W + Ibrutinib 420mgVAY736 1mg/kg Q2W + Ibrutinib 420mgVAY736 3mg/kg Q2W + Ibrutinib 420mgVAY736 9mg/kg Q2W + Ibrutinib 420mgAll Patients Escalation
Time to Progression (TTP) in the Dose Escalation Part23.3 (2.8 to NA)8.3 (1.8 to NA)24.2 (5.6 to NA)19.4 (2.8 to NA)19.4 (2.8 to 25.1)
SecondaryTime to Progression (TTP) in the Dose Expansion Part

Efficacy was based on local investigator assessment per International Working Group - Chronic Lymphocytic Leukemia (IWCLL) response criteria. TTP is defined as the time from start of treatment to date of event which is defined as the first documented progression or death due to underlying cancer. If a patient had not had an event, TTP was censored at the date of the last adequate disease assessment. TTP was analyzed using Kaplan-Meier estimates.

Time frame:
Up to approximately 2.7 years
Reported as:
Median · months
Time to Progression (TTP) in the Dose Expansion Part
monthsVAY736 3mg/kg Q2W Arm A + Ibrutinib 420mgVAY736 3mg/kg Q2W Arm B + Ibrutinib 280mgVAY736 3mg/kg Q2W Arm B + Ibrutinib 420mgAll Patients Expansion
Time to Progression (TTP) in the Dose Expansion PartNA (26.3 to NA)2.3 (NA to NA)NA (NA to NA)NA (26.3 to NA)
SecondaryPercentage of Participants With Clearance of Ibrutinib Resistance Mutation During Treatment (up to C9) for Expansion Arm B

Clearance was defined as less than 1% mutation bearing alleles (BTKC481 and/or PLCγ2) during treatment. Negative mutation is defined as having clearance of the baseline ibrutinib resistance mutation during treatment (up to Cycle 9 (C9)).

Time frame:
Up to Cycle 9 Day 1. The duration of each cycle was 28 days.
Reported as:
Number · percentage of participants
Percentage of Participants With Clearance of Ibrutinib Resistance Mutation During Treatment (up to C9) for Expansion Arm B
percentage of participantsVAY736 3mg/kg Q2W Arm B + Ibrutinib 280mgVAY736 3mg/kg Q2W Arm B + Ibrutinib 420mgAll Patients Expansion Arm B
Percentage of Participants With Clearance of Ibrutinib Resistance Mutation During Treatment (up to C9) for Expansion Arm B0 (0 to 95.0)0 (0 to 52.7)0 (0 to 45.1)
SecondaryMaximum Observed Serum Concentration (Cmax) of VAY736

Pharmacokinetic (PK) parameters were calculated based on VAY736 serum concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed concentration following a dose.

Time frame:
Pre-infusion and 2, 6, 24, 72, 168 and 336 hours after end of infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of the infusion was approximately 2 hours. 1 cycle=28 days
Reported as:
Geometric mean · µg/mL
Maximum Observed Serum Concentration (Cmax) of VAY736
µg/mLVAY736 0.3mg/kg Q2W + Ibrutinib 420mgVAY736 1mg/kg Q2W + Ibrutinib 420mgVAY736 3mg/kg Q2W + Ibrutinib 280mgVAY736 3mg/kg Q2W + Ibrutinib 420mgVAY736 9mg/kg Q2W + Ibrutinib 420mg
Cycle 19.61 ± 23.015.8 ± 59.865.959.4 ± 15.8178 ± 26.7
Cycle 311.2 ± 21.221.6 ± 38.8—72.5 ± 33.9260 ± 13.3
SecondaryTime to Reach Maximum Serum Concentration (Tmax) of VAY736

PK parameters were calculated based on VAY736 serum concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) concentration following a dose. Actual recorded sampling times were considered for the calculations.

Time frame:
Pre-infusion and 2, 6, 24, 72, 168 and 336 hours after end of infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of the infusion was approximately 2 hours. 1 cycle=28 days
Reported as:
Median · hours
Time to Reach Maximum Serum Concentration (Tmax) of VAY736
hoursVAY736 0.3mg/kg Q2W + Ibrutinib 420mgVAY736 1mg/kg Q2W + Ibrutinib 420mgVAY736 3mg/kg Q2W + Ibrutinib 280mgVAY736 3mg/kg Q2W + Ibrutinib 420mgVAY736 9mg/kg Q2W + Ibrutinib 420mg
Cycle 14.30 (2.40 to 6.00)3.90 (2.00 to 5.80)2.20 (2.20 to 2.20)4.70 (2.00 to 6.10)5.80 (2.20 to 6.00)
Cycle 32.00 (2.00 to 2.10)2.20 (2.10 to 2.30)—2.10 (2.00 to 22.70)2.15 (0.00 to 2.70)
SecondaryArea Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of VAY736

PK parameters were calculated based on VAY7736 serum concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation.

Time frame:
Pre-infusion and 2, 6, 24, 72, 168 and 336 hours after end of infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of the infusion was approximately 2 hours. 1 cycle=28 days
Reported as:
Geometric mean · hr*µg/mL
Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of VAY736
hr*µg/mLVAY736 0.3mg/kg Q2W + Ibrutinib 420mgVAY736 1mg/kg Q2W + Ibrutinib 420mgVAY736 3mg/kg Q2W + Ibrutinib 280mgVAY736 3mg/kg Q2W + Ibrutinib 420mgVAY736 9mg/kg Q2W + Ibrutinib 420mg
Cycle 146.0 ± 29.155.5 ± 46.0217256 ± 19.1930 ± 25.0
Cycle 375.6 ± 31.7166 ± 48.2—368 ± 55.21780 ± 18.1
SecondaryMaximum Observed Plasma Concentration (Cmax) of Ibrutinib

PK parameters were calculated based on ibrutinib plasma concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed concentration following a dose.

Time frame:
Pre-dose and 0.5, 2, 6 and 24 hours post-dose on Cycle 1 Day 1 and Cycle 1 Day 8. 1 cycle=28 days
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Ibrutinib
ng/mLVAY736 0.3mg/kg Q2W + Ibrutinib 420mgVAY736 1mg/kg Q2W + Ibrutinib 420mgVAY736 3mg/kg Q2W + Ibrutinib 280mgVAY736 3mg/kg Q2W + Ibrutinib 420mgVAY736 9mg/kg Q2W + Ibrutinib 420mg
Cycle 1 Day 193.5 ± 120.6123 ± 28.821283.3 ± 146.9104 ± 62.7
Cycle 1 Day 894.9 ± 84.4158 ± 53.0—62.2 ± 149.497.0 ± 54.1
SecondaryTime to Reach Maximum Plasma Concentration (Tmax) of Ibrutinib

PK parameters were calculated based on ibrutinib plasma concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) concentration following a dose. Actual recorded sampling times were considered for the calculations.

Time frame:
Pre-dose and 0.5, 2, 6 and 24 hours post-dose on Cycle 1 Day 1 and Cycle 1 Day 8. 1 cycle=28 days
Reported as:
Median · hours
Time to Reach Maximum Plasma Concentration (Tmax) of Ibrutinib
hoursVAY736 0.3mg/kg Q2W + Ibrutinib 420mgVAY736 1mg/kg Q2W + Ibrutinib 420mgVAY736 3mg/kg Q2W + Ibrutinib 280mgVAY736 3mg/kg Q2W + Ibrutinib 420mgVAY736 9mg/kg Q2W + Ibrutinib 420mg
Cycle 1 Day 12.10 (1.90 to 2.10)2.00 (2.00 to 2.10)2.30 (2.30 to 2.30)2.10 (0.60 to 6.80)2.00 (1.90 to 2.20)
Cycle 1 Day 82.00 (1.50 to 6.00)2.00 (1.90 to 2.10)—2.00 (0.50 to 2.50)2.00 (1.90 to 2.00)
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Ibrutinib

PK parameters were calculated based on ibrutinib plasma concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation.

Time frame:
Pre-dose and 0.5, 2, 6 and 24 hours post-dose on Cycle 1 Day 1 and Cycle 1 Day 8. 1 cycle=28 days
Reported as:
Geometric mean · hr*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Ibrutinib
hr*ng/mLVAY736 0.3mg/kg Q2W + Ibrutinib 420mgVAY736 1mg/kg Q2W + Ibrutinib 420mgVAY736 3mg/kg Q2W + Ibrutinib 280mgVAY736 3mg/kg Q2W + Ibrutinib 420mgVAY736 9mg/kg Q2W + Ibrutinib 420mg
Cycle 1 Day 1541 ± 145.3938 ± 63.4890696 ± 98.5634 ± 34.6
Cycle 1 Day 8338 ± 69.6552 ± 41.8—226 ± 134.0323 ± 54.7
SecondaryNumber of Participants With Anti-VAY736 Antibodies

VAY736 immunogenicity was evaluated in serum samples. Anti-drug antibodies (ADA) status was defined as follows: * ADA-negative at baseline: baseline sample where assay is ADA negative * ADA-positive at baseline: baseline sample where assay is ADA positive * ADA-negative post-baseline: ADA-negative sample at baseline and at least 1 post-baseline sample, all of which are ADA-negative samples * Treatment-induced ADA-positive: ADA-negative sample at baseline and at least 1 treatment-induced ADA-positive sample * Treatment-boosted ADA-positive: ADA-positive sample at baseline and at least 1 treatment-boosted ADA-positive sample * ADA-inconclusive post-baseline: patient who does not qualify for any of the above definitions

Time frame:
Baseline (before first dose) and post-baseline (assessed throughout the VAY736 treatment, up to 7.8 months).
Reported as:
Number · participants
Number of Participants With Anti-VAY736 Antibodies
participantsVAY736 0.3mg/kg Q2W + Ibrutinib 420mgVAY736 1mg/kg Q2W + Ibrutinib 420mgVAY736 3mg/kg Q2W + Ibrutinib 280mgVAY736 3mg/kg Q2W + Ibrutinib 420mgVAY736 9mg/kg Q2W + Ibrutinib 420mg
ADA-negative at baseline431244
ADA-positive at baseline00030
ADA-negative post-baseline431244
ADA-inconclusive post-baseline00000
Treatment-induced ADA-positive00000
Treatment-boosted ADA-positive00000
Post-hocAll-Collected Deaths

On-treatment deaths were collected from first dose of study treatment to 30 days after the last dose of VAY736. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study. All deaths refer to the sum of on-treatment and post-treatment deaths.

Time frame:
On-treatment deaths: up to approximately 8.8 months. Post-treatment deaths: up to approximately 2.7 years
Reported as:
Number · participants
All-Collected Deaths
participantsVAY736 0.3mg/kg Q2W + Ibrutinib 420mgVAY736 1mg/kg Q2W + Ibrutinib 420mgVAY736 3mg/kg Q2W + Ibrutinib 280mgVAY736 3mg/kg Q2W + Ibrutinib 420mgVAY736 9mg/kg Q2W + Ibrutinib 420mg
On-treatment deaths00000
Post-treatment deaths00010
All deaths00010

Adverse events

Collected over Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VAY736 0.3mg/kg Q2W + Ibrutinib 420mg0/4 (0%)0/4 (0%)4/4 (100%)
VAY736 1mg/kg Q2W + Ibrutinib 420mg0/3 (0%)2/3 (66.7%)3/3 (100%)
VAY736 3mg/kg Q2W + Ibrutinib 280mg0/1 (0%)0/1 (0%)1/1 (100%)
VAY736 3mg/kg Q2W + Ibrutinib 420mg0/27 (0%)2/27 (7.4%)27/27 (100%)
VAY736 9mg/kg Q2W + Ibrutinib 420mg0/4 (0%)0/4 (0%)4/4 (100%)
All patients_On-treatment0/39 (0%)4/39 (10.3%)39/39 (100%)
VAY736 0.3mg/kg Q2W + Ibrutinib 420mg_Post-treatment0/4 (0%)——
VAY736 1mg/kg Q2W + Ibrutinib 420mg_Post-treatment0/3 (0%)——
VAY736 3mg/kg Q2W + Ibrutinib 280mg_Post-treatment0/1 (0%)——
VAY736 3mg/kg Q2W + Ibrutinib 420mg_Post-treatment1/27 (3.7%)——
VAY736 9mg/kg Q2W + Ibrutinib 420mg_Post-treatment0/4 (0%)——
Most frequent serious events
Most frequent serious events
EventVAY736 0.3mg/kg Q2W + Ibrutinib 420mgVAY736 1mg/kg Q2W + Ibrutinib 420mgVAY736 3mg/kg Q2W + Ibrutinib 280mgVAY736 3mg/kg Q2W + Ibrutinib 420mgVAY736 9mg/kg Q2W + Ibrutinib 420mgAll patients_On-treatmentVAY736 0.3mg/kg Q2W + Ibrutinib 420mg_Post-treatmentVAY736 1mg/kg Q2W + Ibrutinib 420mg_Post-treatmentVAY736 3mg/kg Q2W + Ibrutinib 280mg_Post-treatmentVAY736 3mg/kg Q2W + Ibrutinib 420mg_Post-treatmentVAY736 9mg/kg Q2W + Ibrutinib 420mg_Post-treatment
Escherichia sepsisInfections and infestations0/41/30/10/270/41/39—————
Neutrophil count decreasedInvestigations0/41/30/11/270/42/39—————
Small intestinal obstructionGastrointestinal disorders0/40/30/11/270/41/39—————
Non-cardiac chest painGeneral disorders0/40/30/11/270/41/39—————
Most frequent other events
Showing 10 of 109
Most frequent other events
EventVAY736 0.3mg/kg Q2W + Ibrutinib 420mgVAY736 1mg/kg Q2W + Ibrutinib 420mgVAY736 3mg/kg Q2W + Ibrutinib 280mgVAY736 3mg/kg Q2W + Ibrutinib 420mgVAY736 9mg/kg Q2W + Ibrutinib 420mgAll patients_On-treatmentVAY736 0.3mg/kg Q2W + Ibrutinib 420mg_Post-treatmentVAY736 1mg/kg Q2W + Ibrutinib 420mg_Post-treatmentVAY736 3mg/kg Q2W + Ibrutinib 280mg_Post-treatmentVAY736 3mg/kg Q2W + Ibrutinib 420mg_Post-treatmentVAY736 9mg/kg Q2W + Ibrutinib 420mg_Post-treatment
AnaemiaBlood and lymphatic system disorders2/43/30/18/271/414/39—————
NeutropeniaBlood and lymphatic system disorders0/40/31/10/270/41/39—————
DiarrhoeaGastrointestinal disorders0/43/30/12/272/47/39—————
Neutrophil count decreasedInvestigations1/43/30/14/271/49/39—————
HyperglycaemiaMetabolism and nutrition disorders2/43/30/110/271/416/39—————
VomitingGastrointestinal disorders0/42/30/12/270/44/39—————
ChillsGeneral disorders0/42/30/11/270/43/39—————
PyrexiaGeneral disorders0/42/30/10/270/42/39—————
Platelet count decreasedInvestigations1/42/30/12/270/45/39—————
White blood cell count decreasedInvestigations1/42/30/12/270/45/39—————

Baseline characteristics

Full Analysis Set: All patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.

Age, Continuous
Age, Continuous(years)VAY736 0.3mg/kg Q2W + Ibrutinib 420mgVAY736 1mg/kg Q2W + Ibrutinib 420mgVAY736 3mg/kg Q2W + Ibrutinib 280mgVAY736 3mg/kg Q2W + Ibrutinib 420mgVAY736 9mg/kg Q2W + Ibrutinib 420mgTotal
Mean69.3 ± 6.0261.0 ± 1.7357.063.5 ± 10.3665.0 ± 10.4263.9 ± 9.50
Age, Customized
Age, Customized(Participants)VAY736 0.3mg/kg Q2W + Ibrutinib 420mgVAY736 1mg/kg Q2W + Ibrutinib 420mgVAY736 3mg/kg Q2W + Ibrutinib 280mgVAY736 3mg/kg Q2W + Ibrutinib 420mgVAY736 9mg/kg Q2W + Ibrutinib 420mgTotal
18 - < 65 years13112219
65 - < 85 years30015220
Sex: Female, Male
Sex: Female, Male(Participants)VAY736 0.3mg/kg Q2W + Ibrutinib 420mgVAY736 1mg/kg Q2W + Ibrutinib 420mgVAY736 3mg/kg Q2W + Ibrutinib 280mgVAY736 3mg/kg Q2W + Ibrutinib 420mgVAY736 9mg/kg Q2W + Ibrutinib 420mgTotal
Female0107311
Male42120128
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)VAY736 0.3mg/kg Q2W + Ibrutinib 420mgVAY736 1mg/kg Q2W + Ibrutinib 420mgVAY736 3mg/kg Q2W + Ibrutinib 280mgVAY736 3mg/kg Q2W + Ibrutinib 420mgVAY736 9mg/kg Q2W + Ibrutinib 420mgTotal
White42126336
Black or African American010012
Missing000101
08

Study locations

5 sites
  • University of California San Diego - Moores Cancer Center
    La Jolla, California 92093-0658, United States
  • David Geffen School of Medicine at UCLA
    Los Angeles, California 90095, United States
  • Ohio ST Compr Cancer Ctr James Hosp
    Columbus, Ohio 43210, United States
  • SCRI Oncology Partners
    Nashville, Tennessee 37203, United States
  • Uni of Utah Huntsman Cancer Inst
    Salt Lake City, Utah 84103, United States
09

References and documents

Publications

  • Kipps TJ. Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia. Cancer J. 2021 Jul-Aug 01;27(4):306-313. doi: 10.1097/PPO.0000000000000536. PubMed 34398557 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Sep 2023, 65 months.

Results were first posted in May 2025, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2018
First posted
Jan 17, 2018
StartActual
Apr 9, 2018
Primary completionActual
Sep 29, 2023
CompletionActual
Sep 29, 2023
Results first posted
May 13, 2025
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03400176
Responsible party
Sponsor
First posted
Jan 17, 2018
Start date
Apr 9, 2018
Primary completion
Sep 29, 2023
Completion
Sep 29, 2023
Results posted
May 13, 2025
Last update
May 16, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ianalumab

Start the discussion